bgp-15 and Weight-Gain

bgp-15 has been researched along with Weight-Gain* in 2 studies

Other Studies

2 other study(ies) available for bgp-15 and Weight-Gain

ArticleYear
The HSP co-inducer BGP-15 can prevent the metabolic side effects of the atypical antipsychotics.
    Cell stress & chaperones, 2012, Volume: 17, Issue:4

    Weight gain and dysfunction of glucose and lipid metabolism are well-known side effects of atypical antipsychotic drugs (AAPD). Here, we address the question whether a heat-shock protein (HSP) co-inducer, insulin sensitizer drug candidate, BGP-15, can prevent AAPD-induced glucose, lipid, and weight changes. We also examined how an AAPD alters HSP expression and whether BGP-15 alters that expression. Four different experiments are reported on the AAPD BGP-15 interventions in a human trial of healthy men, a rodent animal model, and an in vitro adipocyte cell culture system. Olanzapine caused rapid insulin resistance in healthy volunteers and was associated with decreased level of HSP72 in peripheral mononuclear blood cells. Both changes were restored by the administration of BGP-15. In Wistar rats, weight gain and insulin resistance induced by clozapine were abolished by BGP-15. In 3T3L1 adipocytes, clozapine increased intracellular fat accumulation, and BGP-15 inhibited this process. Taken together, our results indicate that BGP-15 inhibits multiple metabolic side effects of atypical antipsychotics, and this effect is likely to be related to its HSP co-inducing ability.

    Topics: Adipocytes; Animals; Antipsychotic Agents; Cells, Cultured; Female; HSP72 Heat-Shock Proteins; Humans; Hypoglycemic Agents; Male; Oximes; Piperidines; Rats; Rats, Wistar; Up-Regulation; Weight Gain

2012
A novel insulin sensitizer drug candidate-BGP-15-can prevent metabolic side effects of atypical antipsychotics.
    Pathology oncology research : POR, 2012, Volume: 18, Issue:4

    Atypical antipsychotic drugs (AAPD) are widely used to treat severe psychiatric disorders, have well documented metabolic side effects such as disturbances in glucose metabolism, insulin resistance and weight gain. It has been shown that BGP-15, a hydroxylamine derivative with insulin sensitizing activity can prevent AAPD provoked fat accumulation in adipocyte cultures, and insulin resistance in animal experiments and in healthy volunteers. The aim of this study was to compare the preventive effect of BGP-15 with conventional oral antidiabetics on metabolic side effects of AAPDs. We found that BGP-15 that does not belong to either conventional insulin sensitizers or oral antidiabetics, is able to counteract insulin resistance and weight gain provoked by antipsychotic agents in rats while rosiglitazone and metformin were not effective in the applied doses. Our results confirm that BGP-15 is a promising new drug candidate to control the metabolic side effects of atypical antipsychotics. Data indicate that this rat model is suitable to analyze the metabolic side effects of AAPDs and the protective mechanism of BGP-15.

    Topics: Analysis of Variance; Animals; Antipsychotic Agents; Drug Interactions; Female; Glucose Clamp Technique; Insulin Resistance; Oximes; Piperidines; Protective Agents; Rats; Rats, Wistar; Weight Gain

2012